文献速递淋巴瘤

淋巴瘤免疫治疗的基础免疫学原理

Fundamentals of immunology for understanding immunotherapy for lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

本文综述了淋巴瘤中抗肿瘤免疫应答失败的原因及免疫治疗策略。肿瘤微环境通过MHC表达缺失、免疫抑制配体上调、抑制性免疫细胞及细胞因子等机制导致免疫应答不足。成功的免疫治疗通过促进抗原呈递、激活T细胞与NK细胞、阻断免疫检查点等恢复有效抗肿瘤免疫,已在多种淋巴瘤亚型中获成功并纳入临床实践。

要点

  • 淋巴瘤免疫治疗目标是恢复有效抗肿瘤免疫并建立免疫记忆。
  • 肿瘤微环境通过MHC缺失、抑制性配体及细胞因子等导致免疫应答不足。
  • 促进抗原呈递、激活T/NK细胞及阻断检查点等策略已获临床成功。

核心结论

  • 淋巴瘤患者未能产生有效抗肿瘤免疫应答,导致疾病持续和进展。
  • 免疫治疗通过促进免疫识别、优化免疫激活和维持免疫应答持久性来恢复抗肿瘤免疫。
  • 多种免疫治疗策略已在淋巴瘤各亚型中获成功并纳入标准临床实践。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 肿瘤微环境中存在多种机制导致免疫应答不足,包括肿瘤细胞MHC表达缺失和抗原呈递不足。
  • 恶性细胞免疫抑制配体表达增加、肿瘤内抑制性免疫细胞群及促免疫耗竭或抑制的细胞因子参与免疫逃逸。
  • 成功的免疫治疗策略针对上述问题,促进抗原呈递、改善恶性细胞识别、直接激活T细胞和自然杀伤细胞、阻断免疫检查点信号。

临床怎么用

  • 免疫治疗策略通过促进抗原呈递、激活T细胞和NK细胞、阻断免疫检查点等机制恢复抗肿瘤免疫。
  • 多种免疫治疗方法已在淋巴瘤患者中证实高度成功并纳入标准临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient's disease. The goals of immunotherapy are therefore to restore an effective antitumor immune response by promoting immune recognition, optimizing immune activation, and supporting persistence of the immune response resulting in subsequent immunological memory. Multiple mechanisms, however, are present within the tumor microenvironment that account for an inadequate immune response. These include loss of major histocompatibility complex expression on tumor cells and subsequent inadequate antigen presentation, increased expression of immunosuppressive ligands on malignant cells, populations of immune cells with suppressive function present in the tumor, and cytokines secreted by the malignant cell or other cells in the microenvironment that promote immune exhaustion or suppress the immune response. Successful immunotherapeutic strategies are specifically addressing these issues by promoting antigen presentation, improving recognition of the malignant cell, directly activating T cells and natural killer cells, and blocking immune checkpoint signaling that would suppress the immune response. Many of these approaches have proven highly successful in patients with various subtypes of lymphoma and are now being incorporated into standard clinical practice.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ansell SM. Fundamentals of immunology for understanding immunotherapy for lymphoma. Blood Adv. 2020. PMID: 33232478. doi:10.1182/bloodadvances.2020002537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。